Literature DB >> 24976937

Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review.

Beverly Long1, Ramez N Eskander1, Krishnansu S Tewari1.   

Abstract

Recent retrospective studies have reported the use of stereotactic radiosurgery (SRS) in the treatment of gynecologic cancers. SRS uses real-time imaging and high dose radiation beams attached to precise robotic arms to target malignant lesions while sparing normal tissue. The purpose of this review is to examine the indications for SRS in gynecologic oncology, review the current literature regarding the use of SRS in gynecologic cancers, and identify future directions for research in this area. Literature on stereotactic radiosurgery was reviewed using the PubMed search engine. Articles written in English from 1993-2013 were reviewed, and 20 case series and clinical trials were included. The safety and efficacy SRS has been demonstrated in all gynecologic disease sites including cervical, endometrial, vulvar, vaginal, and ovarian cancers. Indications for its use include non-central pelvic recurrences in previously irradiated patients, complex or non-resectable disease recurrence, and solitary brain metastases. Toxicities are usually mild, though grade 3-4 toxicities have been reported. SRS is a promising second line treatment modality for patients with primary or recurrent disease who cannot undergo standard surgical or radiation therapy. Further research is required to determine optimal dosing and fractionation schedules, delineate appropriate patient populations, and assess longterm morbidity and survival.

Entities:  

Keywords:  Gynecologic oncology; Stereotactic body radiotherapy; Stereotactic radiosurgery

Year:  2014        PMID: 24976937      PMCID: PMC4072821          DOI: 10.4329/wjr.v6.i6.366

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  20 in total

1.  Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system.

Authors:  Joshua Y Menendez; David F Bauer; Chevis N Shannon; John Fiveash; James M Markert
Journal:  J Neurooncol       Date:  2012-07-03       Impact factor: 4.130

Review 2.  Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology.

Authors:  Daniel S Higginson; David E Morris; Ellen L Jones; Daniel Clarke-Pearson; Mahesh A Varia
Journal:  Gynecol Oncol       Date:  2010-12-30       Impact factor: 5.482

3.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.

Authors:  Ji-Hong Hong; Chien-Sheng Tsai; Chyong-Huey Lai; Ting-Chang Chang; Chun-Chieh Wang; Hung-Hsueh Chou; Steve P Lee; Swei Hsueh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

5.  Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy.

Authors:  Charles Kunos; Vivian von Gruenigen; Steven Waggoner; James Brindle; Yuxia Zhang; Brenda Myers; Gary Funkhouser; Barry Wessels; Douglas Einstein
Journal:  Technol Cancer Res Treat       Date:  2008-10

6.  Stereotactic radiotherapy in recurrent gynecological cancer: a case series.

Authors:  Francesco Deodato; Gabriella Macchia; Luca Grimaldi; Gabriella Ferrandina; Domenica Lorusso; Vanda Salutari; Savino Cilla; Vincenzo Valentini; Numa Cellini; Angelo Piermattei; Giovanni Scambia; Alessio Giuseppe Morganti
Journal:  Oncol Rep       Date:  2009-08       Impact factor: 3.906

7.  Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer.

Authors:  P Jain; R D Hunter; J E Livsey; C Coyle; R Swindell; S E Davidson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-12       Impact factor: 4.126

8.  CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy.

Authors:  Jonathan Andrew Haas; Matthew R Witten; Owen Clancey; Karen Episcopia; Diane Accordino; Eva Chalas
Journal:  Front Oncol       Date:  2012-03-21       Impact factor: 6.244

9.  Should helical tomotherapy replace brachytherapy for cervical cancer? Case report.

Authors:  Chen-Hsi Hsieh; Ming-Chow Wei; Yao-Peng Hsu; Ngot-Swan Chong; Yu-Jen Chen; Sheng-Mou Hsiao; Yen-Ping Hsieh; Li-Ying Wang; Pei-Wei Shueng
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

10.  Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer.

Authors:  Gregory J Kubicek; Jinyu Xue; Qianyi Xu; Sucha O Asbell; Leslie Hughes; Noel Kramer; Ashraf Youssef; Yan Chen; James Aikens; Howard Saul; Niraj Pahlajani; Tamara LaCouture
Journal:  Biomed Res Int       Date:  2013-08-13       Impact factor: 3.411

View more
  3 in total

1.  Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer.

Authors:  Charles A Kunos; Tracy M Sherertz; Mazen Mislmani; Rodney J Ellis; Simon S Lo; Steven E Waggoner; Kristine M Zanotti; Karin Herrmann; Robert L Debernardo
Journal:  Front Oncol       Date:  2015-06-05       Impact factor: 6.244

2.  Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.

Authors:  Shaakir Hasan; Anthony Ricco; Kaylette Jenkins; Rachelle Lanciano; Alexandra Hanlon; John Lamond; Jun Yang; Jing Feng; Michael Good; Joel Noumoff; Luther Brady
Journal:  Front Oncol       Date:  2016-11-22       Impact factor: 6.244

Review 3.  Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review.

Authors:  Haruo Matsushita; Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Katagiri; Noriyuki Kadoya
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.